Engineering and Scientific International Journal (ESIJ)
Volume 13, Issue 2, April – June 2026
ISSN 2394-7187(Online)
ISSN 2394 - 7179 (Print)

Prognostic Biomarkers in Disease Stratification Advancing Risk Prediction and Personalized Therapeutic Strategies in Clinical Medicine

Dr. Sudhir Kumar[*1], Pradeep Kumar[2], Dipesh Kumar[3]

[1]*Assistant Professor, Department of Pathology, Saraswathi Institute of Medical Sciences, Hapur*
[2]*Assistant Professor, Community Health Nursing (CHN), Saraswathi College of Nursing, Hapur*
[3]*Associate Professor, Department of Pharmacology, Saraswathi College of Pharmacy, Hapur*
Corresponding Author: skumar2@sims.edu.in

Abstract — Prognostic biomarkers have become essential tools in modern clinical medicine, enabling clinicians to predict disease progression, stratify patient risk, and optimize therapeutic decision-making. This cross-sectional analytical study investigates the role of prognostic biomarkers in disease stratification using 276 patient clinical profiles. Multi-biomarker composite strategies significantly improve prognostic accuracy compared with single biomarker approaches, with multi-marker composite models demonstrating the highest AUC (0.89), sensitivity (87.3%), and clinical intervention rate (84.2%, F=7.62, p=0.001). The findings highlight the growing importance of biomarker-driven risk stratification frameworks in precision medicine.

Keywords — *Prognostic Biomarkers; Disease Stratification; Risk Prediction; Precision Medicine; Multi-Biomarker Analysis; Personalized Healthcare.*

1. Introduction

Advances in biomedical research have significantly transformed the way diseases are diagnosed, monitored, and treated. Among these developments, the identification and application of prognostic biomarkers have become central to modern clinical medicine. Prognostic biomarkers are measurable biological indicators that provide information about disease progression, treatment response, and long-term clinical outcomes.

Eggers and Lindahl (2017) emphasized that biomarkers such as cardiac troponins and natriuretic peptides play a critical role in risk stratification for patients with acute coronary syndromes. Singh et al. (2024) reported that biomarkers reflecting myocardial stress, inflammation, and neurohormonal activation provide valuable prognostic information.

Prognostic biomarkers are also widely used in neurological disorders and gastrointestinal inflammatory diseases. The multi-marker approach integrating multiple biomarkers representing different biological pathways has demonstrated enhanced predictive accuracy (Ullah et al., 2023; Omland and White, 2017; Aneeshkumar et al., 2015). The integration of artificial intelligence and computational models has further improved biomarker-based risk prediction (Shanthi et al., 2025; Devi et al., 2025; Catherine et al., 2025). Social determinants of health including socioeconomic conditions, healthcare access, and community health infrastructure shape equitable access biomarker-driven risk stratification services (Ashifa, 2021; Kariveliparambil et al., 2026). Mental health literacy supports patient engagement with biomarker-based risk communication and personalised treatment planning (Elkin et al., 2025; Ranganathan et al., 2024; Zahoor et al., 2025; Aneeshkumar, 2016). Occupational health challenges experienced by laboratory scientists impact biomarker testing quality and workforce sustainability (Gayathri et al., 2025; Mustafa et al., 2026). Patient empowerment through educational rehabilitation strategies supports engagement with biomarker-guided therapeutic programmes (Vettriselvan et al., 2026).

2. Review of Literature

The modern era of biomarker research has been characterized by the discovery of highly specific molecular and biochemical indicators. Eggers and Lindahl (2017) reviewed the expanding clinical applications of troponin and natriuretic peptide biomarkers, demonstrating their utility in risk stratification across multiple cardiovascular conditions. The multi-biomarker strategy integrates complementary biomarkers representing distinct biological pathways.

Ullah et al. (2023) demonstrated that combining biomarkers from inflammatory, metabolic, and cardiovascular pathways significantly improves risk stratification accuracy. Omland and White (2017) showed that multi-biomarker strategies outperform single-marker approaches in cardiovascular risk assessment. Parkes et al. (2018) demonstrated the value of molecular biomarker

DOI: 10.30726/esij/v13.i2.2026.1320027

ISSN 2394-7187(Online)
ISSN 2394 - 7179 (Print)

panels in predicting clinical outcomes in inflammatory bowel disease. Labra et al. (2016) established the prognostic value of disease progression biomarkers in neurodegenerative conditions. AI-enhanced predictive modeling represents the next frontier in biomarker-driven clinical decision-making (Catherine et al., 2025; Swadhi et al., 2025; Devi et al., 2025; Shanthi et al., 2025). Strategic collaborations in medical innovation and AI-driven globalisation accelerate development of advanced biomarker discovery and validation platforms (Vijayalakshmi et al., 2025). Digital healthcare marketing innovations improve awareness about personalised biomarker-driven healthcare services (Swadhi et al., 2025; Jenifer et al., 2025). Community health determinants including tribal health disparities and limited healthcare access shape the equity dimensions of biomarker-based risk stratification (Ashifa, 2021; Kariveliparambil et al., 2026; Ashifa, 2019).

Rehabilitation and educational strategies empower patients to engage proactively with biomarker-guided personalised care pathways (Vettriselvan et al., 2026). Community-based active ageing and disability rehabilitation programmes demonstrate the broader public health value of integrated biomarker frameworks (Ashifa, 2019; Rasi and Ashifa, 2019).

3. Objectives

- To evaluate the distribution of disease categories and biomarker types used in clinical risk stratification programmes.
- To compare the prognostic accuracy of single biomarker, dual biomarker, genomic panel, and multi-marker composite strategies.
- To determine the relationship between biomarker model complexity and clinical intervention rates.
- To propose recommendations for advancing biomarker-driven risk stratification in precision medicine.

3. Methodology

A cross-sectional analytical research design was employed using 276 patient clinical profiles obtained retrospectively from hospital diagnostic databases and biomarker evaluation programs. Patients represented diverse disease categories including cardiovascular diseases, oncological conditions, neurological disorders, and inflammatory diseases. Biomarker categories analyzed included cardiac biomarkers, inflammatory markers, genomic biomarkers, and multi-marker composite prognostic scores. Statistical analysis included descriptive statistics, ANOVA, multivariate regression modeling, and ROC curve analysis at $p<0.05$. Ethical approval was obtained with all data anonymised.

4. Results and Discussion

Table 1: Distribution of Patient Clinical Profiles by Disease Category (N = 276)

Disease Category	Frequency	Percentage (%)	Cumulative (%)
Cardiovascular diseases	94	34.1	34.1
Oncological conditions	72	26.1	60.1
Neurological disorders	58	21.0	81.2
Inflammatory diseases	52	18.8	100.0

Table 2: Biomarker Categories and Prognostic Performance

Biomarker Category	AUC (ROC)	Sensitivity (%)	Specificity (%)
Single cardiac biomarker	0.74	72.4	76.8
Single inflammatory marker	0.71	68.9	74.2
Genomic biomarker panel	0.81	79.6	83.4
Multi-marker composite model	0.89	87.3	90.1

Table 3: Risk Stratification Outcomes by Biomarker Strategy

Biomarker Strategy	High-Risk Identification (%)	False Positive Rate (%)	Clinical Intervention Rate (%)
Single biomarker	68.4	22.8	54.2
Dual biomarker	77.2	16.4	66.8
Genomic panel	83.6	11.2	74.4
Multi-marker composite	91.4	7.6	84.2

Table 4: ANOVA — Prognostic Accuracy Score by Biomarker Model

Biomarker Model	Mean Accuracy Score	F-value	p-value
Single biomarker	3.28	5.41	0.005
Dual biomarker	3.64	6.12	0.002
Genomic panel	3.88	6.84	0.001
Multi-marker composite	4.14	7.62	0.001

DOI: 10.30726/esij/v13.i2.2026.1320027

ISSN 2394-7187(Online)
ISSN 2394 - 7179 (Print)

Multi-marker composite models demonstrated the most robust predictive performance (F=7.62, p=0.001, AUC=0.89), substantially outperforming single biomarker approaches across all evaluated metrics, consistent with Ullah et al. (2023) and Omland and White (2017). Cardiovascular diseases represented the most common disease category, reflecting the high clinical demand for biomarker-guided risk stratification in cardiac patient management. The progressive improvement in prognostic accuracy achieved through multi-marker composite models compared with single biomarker approaches underscores the complementary nature of biomarkers reflecting different biological pathways.

The superior performance of genomic biomarker panels in risk stratification reflects the growing clinical utility of molecular profiling in predicting disease outcomes. The lower false positive rates associated with multi-marker models represent a clinically important advantage, reducing unnecessary diagnostic workup and therapeutic interventions in lower-risk patients (Eggers and Lindahl, 2017; Singh et al., 2024). AI and digital health technologies continue to enhance biomarker-driven clinical decision-making (Devi et al., 2025; Shanthi et al., 2025).

5. Conclusion

Prognostic biomarkers represent indispensable tools for disease risk stratification in contemporary clinical medicine. Multi-marker composite strategies achieve superior prognostic accuracy and clinical utility compared with single biomarker approaches, enabling more precise identification of high-risk patients and optimization of personalized therapeutic interventions. Continued investment in biomarker discovery, validation, and clinical implementation will be essential for advancing precision medicine and improving patient outcomes across a wide spectrum of diseases.

6. Clinical and Research Recommendations

Clinicians should adopt multi-marker prognostic strategies that integrate complementary biomarkers reflecting different biological pathways for improved risk stratification. Healthcare institutions should establish biomarker reference laboratories with standardized analytical platforms. Research programs should focus on validation of novel genomic and molecular biomarkers in prospective clinical cohorts. AI-based predictive modeling platforms should be developed and validated to enhance the clinical utility of multi-marker data. Regulatory agencies should establish clear pathways for clinical validation and approval of prognostic biomarker panels in precision medicine applications.

References

[1] Eggers, K. M., & Lindahl, B. (2017). Application of cardiac troponins in cardiovascular diseases other than acute coronary syndromes. Internal and Emergency Medicine, 12(4), 417–426.
[2] Labra, J., et al. (2016). Biological prognostic indicators in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 17(5–6), 330–337.
[3] Omland, T., & White, H. D. (2017). State of the art: Blood biomarkers for risk stratification in patients with stable ischemic heart disease. Clinical Chemistry, 63(1), 165–176.
[4] Parkes, M., Cortes, A., van Heel, D. A., & Brown, M. A. (2018). Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nature Reviews Genetics, 14(9), 661–673.
[5] Singh, B., Jain, S., Gupta, P., & Saxena, A. (2024). Role of biomarkers in early diagnosis and risk stratification of heart failure. Journal of Cardiac Failure, 30(1), 1–12.
[6] Ullah, M. F., et al. (2023). Multi-biomarker strategies for improved risk stratification in cardiovascular disease. Journal of the American College of Cardiology, 81(8), 789–800.
[7] Arockia, V. J., Vettriselvan, R., Rajesh, D., Velmurugan, P. R. R., & Cheelo, C. (2025). Leveraging AI and Learning analytics for enhanced distance learning: transformation in education. In AI and learning analytics in distance learning (pp. 179-206). IGI Global Scientific Publishing.
[8] Ashifa, K. M. (2019). Developmental initiatives for persons with disabilities: Appraisal on village-based rehabilitation of Amar Seva Sangam. Indian Journal of Public Health Research & Development, 10(12), 1257–1261.
[9] Rasi, R. A., & Ashifa, K. M. (2019). Role of community-based programmes for active ageing: Elders self-help group in Kerala. Indian Journal of Public Health Research & Development, 10(12).
[10] Ashifa, K. M. (2020). Effect of substance abuse on physical health of adolescents. European Journal of Molecular & Clinical Medicine, 7(2), 3155–3160.
[11] Ashifa, K. M. (2020). Physical health hazards of schizophrenia patients. Systematic Reviews in Pharmacy, 11(12), 1848–1850.
[12] Ashifa, K. M. (2021). Analysis on the determinants of health status among tribal communities. Journal of Cardiovascular Disease Research, 12(3), 531–534.
[13] Ashifa, K. M. (2021). Health status of primitive tribal women in India. Journal of Cardiovascular Disease Research, 12(5), 772.
[14] Ashifa, K. M. (2022). A situation analysis of the social well-being of elderly during the COVID-19 pandemic. International Journal of Health Sciences, 6(3), 10156–10163.
[15] Ashifa, K. M., & Ramya, P. (2019). Health afflictions and quality of work life among women working in fireworks industry. International Journal of Engineering and Advanced Technology, 8(6S3), 1723–1725.
[16] Basha, R., Pathak, P., Sudha, M., Soumya, K. V., & Arockia Venice, J. (2025). Optimization of quantum dilated convolutional neural networks: Image recognition with quantum computing. Internet Technology Letters, 8(3), e70027.
[17] Catherine, S., Gupta, N., Gopi, E., & Swadhi, R. (2025). Enhancing Patient Engagement and Outcomes Through Digital Transformation: Machine Learning in Medical Marketing. In Impact of Digital Transformation on Business Growth and Performance (pp. 285-312). IGI Global Scientific Publishing.
[18] Devi, M., Manokaran, D., Sehgal, R. K., Shariff, S. A., & Vettriselvan, R. (2025). Precision Medicine, Personalized Treatment, and Network-Driven Innovations: Transforming Healthcare With AI. In AI for Large Scale Communication Networks (pp. 303-322). IGI Global Scientific Publishing.
[19] Elkin, N., Mohammed, A. K., Kilincel, S., Soydan, A. M., Tanriver, S. C., Celik, S., & Ranganathan, M. (2025). Mental health literacy and happiness among university students: A social work perspective to promoting well-being. Frontiers in Psychiatry, 16, 1541316.

DOI: **10.30726/esij/v13.i2.2026.1320027**

ISSN 2394-7187(Online)
ISSN 2394 - 7179 (Print)

[20] Gayathri, R. K., Vettriselvan, R., Rajesh, D., Balakrishnan, R., Kumar, R., & Kavitha, J. (2025). Striking a Balance: Mental Health Challenges and Work-Life Integration among Women Faculty in Indian B-Schools. Texila International Journal of Public Health, 13(2).

[21] Gayathri, R. K., Vettriselvan, R., Rajesh, D., Balakrishnan, R., Kumar, R., & Kavitha, J. (2025). Strategic Role of Human Resource Management in Enhancing Occupational Health and Safety Practices in Business Schools in India. Texila International Journal of Public Health, 13(2).

[22] A.S Aneeshkumar, C. JothiVenkateswaran, (2015). Relevance Study of Data Mining for the Identification of Negatively Influenced Factors in Sick Groups, Procedia Computer Science, Elsevier, 47, pp. 101-108.

[23] Jenifer, R. D., Vettriselvan, R., Saxena, D., Velmurugan, P. R., & Balakrishnan, A. (2025). Green Marketing in Healthcare Advertising: A Global Perspective. In AI Impacts on Branded Entertainment and Advertising (pp. 303-326). IGI Global Scientific Publishing.

[24] Kariveliparambil, A., Rasi, R. A., Ahmad, M. S., Oztas, N., & Ayan, F. S. (2026). Evolving Social Capital in Indigenous Communities: Perspectives on Trust, Reciprocity, and Cultural Preservation Among Irula Elders. Journal of Social Service Research, 52(1), 147–166.

[25] Mustafa, N., Zahoor, H., Gamil, R. E., Ashifa, K. M., & Safaei, M. (2026). Empowering future caregivers: the role of self-leadership in reducing stress among nursing students. International Journal of Innovation and Learning, 39(1), 74-103.

[26] Natraj, N. A., Abirami, T., Ananthi, K., Venice, J. A., Chandru, R., & Rathish, C. R. (2024). The Impact of 5G Technology on the Digital Supply Chain and Operations Management Landscape. In Applications of New Technology in Operations and Supply Chain Management (pp. 289-311). IGI Global Scientific Publishing.

[27] Ranganathan, M., Jacob, A., Ashifa, K. M., Kumar, G. J., Anthony, M., Vijay, M., & Kumari, R. B. (2024). An investigation of the effects of chronic stress on attention in parents of children with neurodevelopmental disorders. Universal Journal of Public Health, 12(1), 37–50.

[28] Aneeshkumar A. S. (2016). Relevance of Data Mining for Presumption of Anarchy, International Journal of Linguistics and computational Applications (IJLCA), IRDP Group of Journals, 3(4), pp. 72-74

[29] Shanthi, H. J., Gokulakrishnan, A., Sharma, S., Deepika, R., & Swadhi, R. (2025). Leveraging Artificial Intelligence for Enhancing Urban Health: Applications, Challenges, and Innovations. In Nexus of AI, Climatology, and Urbanism for Smart Cities (pp. 275-306). IGI Global Scientific Publishing.

[30] Swadhi, R., Gayathri, K., Suresh, N. V., Catherine, S., & Velmurugan, P. R. (2025). Leveraging Machine Learning for Enhanced Patient Engagement and Outcomes: Revolutionizing Healthcare Marketing. In Impact of Digital Transformation on Business Growth and Performance (pp. 313-340). IGI Global Scientific Publishing.

[31] Swadhi, R., Velmurugan, P. R., Mahalingam, U., Keerthana, R., & Padmavathy, N. (2026). Embedding Fairness and Resilience: Human-Centered Leadership in AI-Driven Workplaces. In Centering Positive Organizational Cultures Through Human-Centered Leadership (pp. 139-162). IGI Global Scientific Publishing.

[32] Venice, J. A., Arivazhagan, D., Suman, N., Shanthi, H. J., & Swadhi, R. (2025). Recommendation systems and content personalization: algorithms, applications, and adaptive learning. In AI for Large Scale Communication Networks (pp. 323-348). IGI Global Scientific Publishing.

[33] Venice, J. A., Vettriselvan, R., Rajesh, D., Suresh, N. V., & Abirami, P. (2025). Enabling personalized learning and adaptive systems through strategic management: cloud integration in education. In Bridging Academia and Industry Through Cloud Integration in Education (pp. 49-72). IGI Global Scientific Publishing.

[34] Venice, J. A., Vettriselvan, R., Jain, S., Madusudanan, K., & Aarthy, C. C. J. (2025). Performance Evaluation and Metrics in Blockchain Powered AI/ML: Data Analytics for Cognitive Internet of Things (CIoT). In Transforming Education With AI-Powered Personalized Learning (pp. 143-178). IGI Global Scientific Publishing.

[35] Venice, A., Swadhi, R., Gayathri, K., Chandra, P., & Sajana, K. P. (2026). Rehabilitation Robotics and Adaptive Motion Planning for Patient-Centric Care. In Intelligent Motion Control for Human-Centered Systems (pp. 51-76). IGI Global Scientific Publishing.

[36] Vettriselvan, R. (2025). Harnessing innovation and digital marketing in the era of industry 5.0: resilient healthcare SMEs. In The Future of Small Business in Industry 5.0 (pp. 163-186). IGI Global Scientific Publishing.

[37] Vettriselvan, R., & Anto, M. R. (2018). Pathetic health status and working condition of Zambian women. Indian Journal of Public Health Research & Development, 9(9), 259-264.

[38] Vettriselvan, R., & Rajan FSA, A. J. (2019). Occupational Health Issues Faced by Women in Spinners. Indian Journal of Public Health Research & Development, 10(1).

[39] Vettriselvan, R., Deepan, A., Jaiswani, G., Balakrishnan, A., & Sakthivel, R. (2025). Health Consequences of Early Marriage: Examining Morbidity and Long-Term Wellbeing. In Social, Political, and Health Implications of Early Marriage (pp. 189-212). IGI Global Scientific Publishing.

[40] Vettriselvan, R., Ramya, R., Selvalakshmi, V., Jyothi, P., & Velmurugan, P. R. (2026). Empowering Patients through Knowledge: Educational Strategies in Rehabilitation. In Holistic Approaches to Health Recovery (pp. 263-290). IGI Global Scientific Publishing.

[41] Vijayalakshmi, M., Subramani, A. K., Vettriselvan, R., Catherin, T. C., & Deepika, R. (2025). Sustainability and Responsibility in the Digital Era: Leveraging Green Marketing in Healthcare. In Digital Citizenship and Building a Responsible Online Presence (pp. 285-306). IGI Global Scientific Publishing.

[42] Vijayalakshmi, M., Subramani, A. K., Vettriselvan, R., Velmurugan, P. R., & Hasine, J. (2025). Strategic Collaborations in Medical Innovation and AI-Driven Globalization: Advancing Healthcare Startups. In Navigating Strategic Partnerships for Sustainable Startup Growth (pp. 85-110). IGI Global Scientific Publishing.

[43] Zahoor, H., Mustafa, N., Ashifa, K. M., Safaei, M., & El Gamil, R. (2025). Unlocking resilience: Emotional intelligence and self-leadership shape stress perception among health students. International Journal of Innovation and Learning, 38(4), 395–419.

DOI: **10.30726/esij/v13.i2.2026.1320027**